Ignite Creation Date:
2025-12-25 @ 4:30 AM
Ignite Modification Date:
2026-03-05 @ 6:35 PM
Study NCT ID:
NCT05722418
Status:
RECRUITING
Last Update Posted:
2025-09-25
First Post:
2022-12-19
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Sponsor:
Caribou Biosciences, Inc.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Relapsed/Refractory Multiple Myeloma | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | CaMMouflage | View |
| None | Allogeneic | View |
| None | Multiple Myeloma | View |
| None | Relapse Refractory Multiple Myeloma | View |
| None | CAR-T Cells | View |
| None | BCMA | View |
| None | Cell Therapy | View |
| None | Cellular Immuno-therapy | View |
| None | CB11A | View |
| None | CB-011 | View |
| None | CB-011A | View |
| None | CAR-T | View |
| None | Anti BCMA | View |
| None | ALLO CAR T | View |